There are 8 stocks in the munKNEE Psychedelic Drug Stocks Index and here is how its constituents performed in October (as of October 27th*):

1. Allied Corp. (ALID): UP 15.6% in October*
   • Has a product in a Phase I clinical trial in Columbia for treating post-traumatic stress disorder.
2. Cybin (CYBN): DOWN 2.1% in October*
   • Is focused on utilizing proprietary drug discovery platforms, innovative drug delivery systems, novel formulation approaches and treatment regimens for psychiatric disorders.
3. Zynerba (ZYNE): DOWN 4.1% in October*
   • Is focused on developing and commercializing synthetic cannabinoid therapeutics formulated for transdermal delivery.
4. Compass Pathways (CMPS): DOWN 4.3% in October*
   • Is focused on the development of psilocybin therapy for people with Treatment-Resistant Depression.
5. Atai (ATAI): DOWN 9.7% in October*
   • Is focused on acquiring and developing treatments that lead to paradigm shifts in the mental health space.
6. GH Research (GHRS): DOWN 13.9% in October*
   • Is focused on developing 5-MeO-DMT therapies for the treatment of patients with Treatment-Resistant Depression.
7. Mind Medicine (MNMD): DOWN 16.9% in October*
   • Is focused on discovering, developing, and deploying therapies to address addiction and mental illness development.
   • Underwent a 1-for-15 reverse stock exchange on August 29th.
8. Seelos (SEEL): DOWN 18.4% in October*
   • Is focused on developing products for the treatment of Central Nervous System disorders and other rare disorders.

In total, the munKNEE Psychedelic Drug Stock Index went DOWN 9.9% in September and is now DOWN 64.7% YTD.

Six other psychedelic companies are primarily focused on the development, expansion, and operation of ketamine-assisted therapy (KAT) clinics to capitalize on the massive commercial opportunity that exists to treat the two billion people worldwide who suffer from chronic pain, addiction, and substance abuse withdrawal, and depression. They are identified below with a description of each of their commercialization developments:

1. Awakn Life Sciences Corp.  (NEO: AWAKN|OTCQB: AWKNF)
   • Is concentrating on the treatment of Alcohol Use Disorder (AUM)
     • has 3 KAT clinics, 2 in the U.K. and 1 in Norway and
     • is developing MDMA-assisted therapy for AUM
   •  Is also in the process of developing KAT for Gambling Disorder
   • Go here for the company's latest quarterly (Q2) financial results
2. Delic Corp. (CSE: DELC|OTCQB: DELCF)
   • Has 13 ketamine-assisted therapy (KAT) clinics in the U.S.
3. Field Trip Health and Wellness Ltd. (TSXV: FTHW|OTCQB: FTHWF)
   • Is concentrating on therapies for the treatment of resistant depression, post-traumatic stress disorder and disorders affecting the central nervous systems
   • Operates KAT clinics in Canada (3), the U.S. (8) and Europe (1)
4. Numinus Wellness Inc. (TSX: NUMI|OTCQX: NUMIF)
   • has 3 KAT clinics in Canada;
   • has the ability to undertake treatments using psilocybin and MDMA in Canada as authorized by Health Canada's Special Access Program
   • Has 6 KAT clinics in Utah and 2 in Arizona
5. Revitalist Lifestyle and Wellness Ltd. (CSE: CALM|OTCQB: RVLWF)
   • Has 10 KAT clinics in 6 states and 9 options on other clinics
6. Universal Ibogaine Inc. (TSXV: IBO|OTCQB: IBOGF)
   • Is concentrating on the treatment of Opioid Use Disorder using ibogaine which has a “Prescription Drug List” status in Canada (vs. Schedule 1 in the US) facilitating research and development toward medicalization

The  above psychedelic-assisted therapy clinic stocks went DOWN 13.4%, on average, in October and has gone DOWN 31.1% since the end of August.

More By This Author:

Suppliers Of Goods & Services To Cannabis Companies Outperformed S&P 500 In October
Highest ESG Score ETFs Index Is Outperforming The S&P In October
AMMO Inc. Aims To Take Business To The Next Level